Zimmer Biomet Holdings Inc
ZIM
Company Profile
Business description
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Contact
345 East Main Street
WarsawIN46580
USAT: +1 574 373-3333
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
17,000
Stocks News & Analysis
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
stocks
Is it time to bail on Australian stocks?
Is your home bias costing your portfolio better returns?
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.50 | 25.20 | 0.28% |
| CAC 40 | 8,140.82 | 50.54 | 0.62% |
| DAX 40 | 25,508.01 | 105.73 | 0.42% |
| Dow JONES (US) | 52,093.11 | 328.09 | -0.63% |
| FTSE 100 | 10,733.60 | 75.47 | 0.71% |
| HKSE | 24,713.78 | 46.54 | 0.19% |
| NASDAQ | 25,981.57 | 204.84 | -0.78% |
| Nikkei 225 | 63,923.00 | 438.90 | 0.69% |
| NZX 50 Index | 13,622.72 | 138.50 | 1.03% |
| S&P 500 | 7,585.73 | 34.25 | -0.45% |
| S&P/ASX 200 | 8,696.50 | 24.00 | 0.28% |
| SSE Composite Index | 3,891.60 | 27.32 | 0.71% |